BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Franklin JM, Schneeweiss S. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials? Clin Pharmacol Ther. 2017;102:924-933. [PMID: 28836267 DOI: 10.1002/cpt.857] [Cited by in Crossref: 138] [Cited by in F6Publishing: 148] [Article Influence: 23.0] [Reference Citation Analysis]
Number Citing Articles
1 de Pouvourville G, Armoiry X, Lavorel A, Bilbault P, Maugendre P, Bensimon L, Beziz D, Blin P, Borget I, Bouée S, Collignon C, Dervaux B, Durand-Zaleski I, Julien M, de Léotoing L, Majed L, Martelli N, Séjourné T, Viprey M. Real-world data and evidence in health technology assessment: When are they complementary, substitutes, or the only sources of data compared to clinical trials? Therapie 2023;78:81-94. [PMID: 36464522 DOI: 10.1016/j.therap.2022.11.001] [Reference Citation Analysis]
2 de Pouvourville G, Armoiry X, Lavorel A, Bilbault P, Maugendre P, Bensimon L, Beziz D, Blin P, Borget I, Bouée S, Collignon C, Dervaux B, Durand-Zaleski I, Julien M, de Léotoing L, Majed L, Martelli N, Séjourné T, Viprey M. Données et preuves en vie réelle dans l’évaluation des technologies de santé : dans quels cas sont-elles complémentaires, substitutives, ou les seules sources de données par rapport aux essais cliniques ? Therapie 2023;78:66-80. [PMID: 36446648 DOI: 10.1016/j.therap.2022.10.067] [Reference Citation Analysis]
3 Loiseau N, Trichelair P, He M, Andreux M, Zaslavskiy M, Wainrib G, Blum MGB. External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning. BMC Med Res Methodol 2022;22:335. [PMID: 36577946 DOI: 10.1186/s12874-022-01799-z] [Reference Citation Analysis]
4 Robert James Trager, Clinton J Daniels, Jaime A Perez, Regina M Casselberry, Jeffery A Dusek. Association between chiropractic spinal manipulation and lumbar discectomy in adults with lumbar disc herniation and radiculopathy: retrospective cohort study using United States’ data. BMJ Open 2022;12:e068262. [PMID: 36526306 DOI: 10.1136/bmjopen-2022-068262] [Reference Citation Analysis]
5 Ito K, Kita Y, Kobayashi T. Real‐world outcomes of pembrolizumab for platinum‐refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial‐unfit patients. Int J of Urology 2022. [DOI: 10.1111/iju.15101] [Reference Citation Analysis]
6 Fang Y, Zhong S. The targeted virtual control approach for single-arm clinical trials with external controls. Statistics in Biopharmaceutical Research 2022. [DOI: 10.1080/19466315.2022.2154260] [Reference Citation Analysis]
7 Chokkalingam AP, Hayden J, Goldman JD, Li H, Asubonteng J, Mozaffari E, Bush C, Wang JR, Kong A, Osinusi AO, Gottlieb RL. Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States. JAMA Netw Open 2022;5:e2244505. [PMID: 36454570 DOI: 10.1001/jamanetworkopen.2022.44505] [Reference Citation Analysis]
8 Carrigan G, Bradbury BD, Brookhart MA, Capra WB, Chia V, Rothman KJ, Sarsour K, Taylor MD, Brown JS. External Comparator Groups Derived from Real-world Data Used in Support of Regulatory Decision Making: Use Cases and Challenges. Curr Epidemiol Rep 2022. [DOI: 10.1007/s40471-022-00305-9] [Reference Citation Analysis]
9 Storino J, Cerini M, Lupinacci L, Specterman S, Cayol F. Inmunoterapia en cáncer de pulmón metastásico. RevOnco 2022;25. [DOI: 10.56969/oc.v25i1.24] [Reference Citation Analysis]
10 Liu F, Demosthenes P. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol 2022;22:287. [DOI: 10.1186/s12874-022-01768-6] [Reference Citation Analysis]
11 Kim MJ, Park YH, Kim HJ, Kang D, Ahn HK, Shin S, Park S, Cho J. Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation (Preprint). Journal of Medical Internet Research 2022. [DOI: 10.2196/43359] [Reference Citation Analysis]
12 Wang J, Gagne JJ, Kattinakere-Sreedhara S, Fischer MA, Bykov K. Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study. BMJ 2022;379:e069931. [PMID: 36195324 DOI: 10.1136/bmj-2021-069931] [Reference Citation Analysis]
13 Sakamoto Y, Bando H, Nakamura Y, Hasegawa H, Kuwaki T, Okamoto W, Taniguchi H, Aoyagi Y, Miki I, Uchigata H, Kuramoto N, Fuse N, Yoshino T, Ohtsu A. Trajectory for the regulatory approval of a combination of pertuzumab plus trastuzumab for pre-treated HER2-positive metastatic colorectal cancer using real-world data. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.10.003] [Reference Citation Analysis]
14 Højlund M, Andersen K, Ernst MT, Correll CU, Hallas J. Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study. World Psychiatry 2022;21:444-51. [PMID: 36073694 DOI: 10.1002/wps.21010] [Reference Citation Analysis]
15 Kirchgesner J, Desai RJ, Schneeweiss MC, Beaugerie L, Schneeweiss S, Kim SC. Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease. Gut 2022;71:1781-9. [PMID: 35387877 DOI: 10.1136/gutjnl-2022-327002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kerr L, Baldi F, Lobo R, Assagra WL, Proença FC, Chamie JJ, Hibberd JA, Kory P, Cadegiani FA. Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects. Cureus 2022. [DOI: 10.7759/cureus.28624] [Reference Citation Analysis]
17 Wang SV, Sreedhara SK, Schneeweiss S; REPEAT Initiative. Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions. Nat Commun 2022;13:5126. [PMID: 36045130 DOI: 10.1038/s41467-022-32310-3] [Reference Citation Analysis]
18 Oostendorp RAB, Elvers H, van Trijffel E, Rutten GM, Scholten-peeters GGM, De Kooning M, Laekeman M, Nijs J, Roussel N, Samwel H. Improved quality of physiotherapy care in patients with Whiplash-Associated Disorders: Results based on 16 years of routinely collected data. Front Pain Res 2022;3. [DOI: 10.3389/fpain.2022.929385] [Reference Citation Analysis]
19 Jang HY, Kim I, Oh JM. Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data. Front Pharmacol 2022;13:928121. [DOI: 10.3389/fphar.2022.928121] [Reference Citation Analysis]
20 Crown W, Dahabreh IJ, Li X, Toh S, Bierer B. Can Observational Analyses of Routinely Collected Data Emulate Randomized Trials? Design and Feasibility of the Observational Patient Evidence for Regulatory Approval Science and Understanding Disease Project. Value Health 2022:S1098-3015(22)02099-X. [PMID: 35970705 DOI: 10.1016/j.jval.2022.07.003] [Reference Citation Analysis]
21 Peng L, Zhang K, Li Y, Chen L, Gao H, Chen H. Real-World Evidence of Traditional Chinese Medicine (TCM) Treatment on Cancer: A Literature-Based Review. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-10. [DOI: 10.1155/2022/7770380] [Reference Citation Analysis]
22 Chang Y, Tu Y, Chiou H, Lai K, Yu NC. Real-world Benefits of Diabetes Management App Use and Self-monitoring of Blood Glucose on Glycemic Control: Retrospective Analyses. JMIR Mhealth Uhealth 2022;10:e31764. [DOI: 10.2196/31764] [Reference Citation Analysis]
23 Trager RJ, Cupler ZA, DeLano KJ, Perez JA, Dusek JA. Association between chiropractic spinal manipulative therapy and benzodiazepine prescription in patients with radicular low back pain: a retrospective cohort study using real-world data from the USA. BMJ Open 2022;12:e058769. [PMID: 35697464 DOI: 10.1136/bmjopen-2021-058769] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Oksen D, Prince P, Boutmy E, Garry EM, Ellers-Lenz B, Estrin A, Johne A, Verpillat P, Gatto NM. Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study. Clin Transl Sci 2022. [PMID: 35661422 DOI: 10.1111/cts.13315] [Reference Citation Analysis]
25 Torres AZ, Nussbaum NC, Parrinello CM, Bourla AB, Bowser BE, Wagner S, Tabano DC, George D, Miksad RA. Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. Adv Ther 2022;39:2831-49. [PMID: 35430670 DOI: 10.1007/s12325-022-02091-8] [Reference Citation Analysis]
26 Zhang P, Tossone K, Ashmead R, Bickert T, Bailey E, Doogan NJ, Mack A, Schmidt S, Bonny AE. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data. J Subst Abuse Treat 2022;136:108686. [PMID: 34953637 DOI: 10.1016/j.jsat.2021.108686] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Pan CQ, Afdhal NH, Ankoma-Sey V, Bae H, Curry MP, Dieterich D, Frazier L, Frick A, Hann HW, Kim WR, Kwo P, Milligan S, Tong MJ, Reddy KR. First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide. Hepatol Commun 2022. [PMID: 35445803 DOI: 10.1002/hep4.1964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 van Laar SA, Gombert-Handoko KB, Groenwold RHH, van der Hulle T, Visser LE, Houtsma D, Guchelaar HJ, Zwaveling J. Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands. Front Pharmacol 2022;13:803935. [PMID: 35401238 DOI: 10.3389/fphar.2022.803935] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Mohr P, Scherrer E, Assaf C, Bender M, Berking C, Chandwani S, Eigentler T, Grimmelmann I, Gutzmer R, Haferkamp S, Hassel J, Hauschild A, Herbst R, Jiang R, Kähler K, Krepler C, Kreuter A, Leiter U, Loquai C, Meier F, Pföhler C, Rudolph A, Schadendorf D, Schiavone M, Schley G, Terheyden P, Ugurel S, Ulrich J, Utikal J, Weishaupt C, Welzel J, Weichenthal M. Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers 2022;14:1804. [DOI: 10.3390/cancers14071804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Thor Petersen C, Jensen KJ, Rosenzweig M, von Osmanski BI, Ankarfeldt MZ, Petersen J. Mapping Outcomes and Registries Used in Current Danish Pharmacoepidemiological Research. CLEP 2022;Volume 14:521-42. [DOI: 10.2147/clep.s341480] [Reference Citation Analysis]
31 Kristensen KB, Lund LC, Jensen PB, Broe A, Rotbain EC, Damkier P, Pottegård A, Andersen J, Højlund M, Olesen M, Rasmussen L, Hansen MR, Ernst MT, Wesselhoeft R, Henriksen DP, Reilev M, Bliddal M, Hallas J. Development and Validation of a Nordic Multimorbidity Index Based on Hospital Diagnoses and Filled Prescriptions. CLEP 2022;Volume 14:567-79. [DOI: 10.2147/clep.s353398] [Reference Citation Analysis]
32 Myles PS. Future of Clinical Trial Methodology. Anesth Analg 2022;134:668-73. [PMID: 35299205 DOI: 10.1213/ANE.0000000000005818] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Gomes M, Latimer N, Soares M, Dias S, Baio G, Freemantle N, Dawoud D, Wailoo A, Grieve R. Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges. Pharmacoeconomics 2022. [PMID: 35332434 DOI: 10.1007/s40273-022-01141-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Wang H, Fang Y, He W, Chen R, Chen S. Clinical Trials with External Control: Beyond Propensity Score Matching. Stat Biosci. [DOI: 10.1007/s12561-022-09341-x] [Reference Citation Analysis]
35 Ghiani M, Maywald U, Wilke T, Heeg B. Bridging the gap between oncology clinical trials and real-world data: evidence on replicability of efficacy results using German claims data. J Comp Eff Res 2022. [PMID: 35315280 DOI: 10.2217/cer-2021-0224] [Reference Citation Analysis]
36 Pawar A, Gagne JJ, Gopalakrishnan C, Iyer G, Tesfaye H, Brill G, Chin K, Bykov K. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism. JAMA 2022;327:1051-60. [PMID: 35289881 DOI: 10.1001/jama.2022.1920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
37 Baumgarten C, Lazard A, Magro E, Roche P, Hamel O, Haegelen C, De Schlichting E. Results of a French pilot database of standard of care of chronic subdural hematoma. Neurochirurgie 2022. [DOI: 10.1016/j.neuchi.2022.01.005] [Reference Citation Analysis]
38 Caissie A, Mierzwa M, Fuller CD, Rajaraman M, Lin A, MacDonald A, Popple R, Xiao Y, VanDijk L, Balter P, Fong H, Xu H, Kovoor M, Lee J, Rao A, Martel M, Thompson R, Merz B, Yao J, Mayo C. Head and Neck Radiation Therapy Patterns of Practice Variability Identified as a Challenge to Real-World Big Data: Results From the Learning from Analysis of Multicentre Big Data Aggregation (LAMBDA) Consortium. Adv Radiat Oncol 2023;8:100925. [PMID: 36711064 DOI: 10.1016/j.adro.2022.100925] [Reference Citation Analysis]
39 Imai T, Hazama K, Kosuge Y, Suzuki S, Ootsuka S. Preventive effect of rebamipide on NSAID-induced lower gastrointestinal tract injury using FAERS and JADER. Sci Rep 2022;12:2631. [PMID: 35173236 DOI: 10.1038/s41598-022-06611-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Lin LA, Zhang Y, Straus W, Wang W. Integrative Analysis of Randomized Clinical Trial and Observational Study Data to Inform Post-marketing Safety Decision-Making. Ther Innov Regul Sci 2022. [PMID: 35138577 DOI: 10.1007/s43441-021-00349-x] [Reference Citation Analysis]
41 Berger ML, Crown W. How Can We Make More Rapid Progress in the Leveraging of Real-World Evidence by Regulatory Decision Makers? Value in Health 2022;25:167-70. [DOI: 10.1016/j.jval.2021.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Loiseau N, Trichelair P, He M, Andreux M, Zaslavskiy M, Wainrib G, Blum MG. External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning.. [DOI: 10.1101/2022.01.28.22269591] [Reference Citation Analysis]
43 Bykov K, Patorno E, D'Andrea E, He M, Lee H, Graff JS, Franklin JM. Prevalence of Avoidable and Bias-Inflicting Methodological Pitfalls in Real-World Studies of Medication Safety and Effectiveness. Clin Pharmacol Ther 2022;111:209-17. [PMID: 34260087 DOI: 10.1002/cpt.2364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Wang SV, Schneeweiss S. Assessing and Interpreting Real-World Evidence Studies: Introductory Points for New Reviewers. Clin Pharmacol Ther 2022;111:145-9. [PMID: 34416020 DOI: 10.1002/cpt.2398] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Wang C, Rosner GL, Bao T, Lu N, Chen WC, Li H, Tiwari R, Xu Y, Yue LQ. Leveraging real-world evidence for determining performance goals for medical device studies. Stat Med 2021;40:6577-89. [PMID: 34561895 DOI: 10.1002/sim.9199] [Reference Citation Analysis]
46 Stimpson G, Chesshyre M, Baranello G, Muntoni F. Lessons Learned From Translational Research in Neuromuscular Diseases: Impact on Study Design, Outcome Measures and Managing Expectation. Front Genet 2021;12:759994. [PMID: 36687260 DOI: 10.3389/fgene.2021.759994] [Reference Citation Analysis]
47 Qi F, Wu Y, Wang J, Wang Q. China's Hainan Free Trade Port: Medical Laws and Policy Reform. Front Public Health 2021;9:764977. [PMID: 34869178 DOI: 10.3389/fpubh.2021.764977] [Reference Citation Analysis]
48 Hong YD, Jansen JP, Guerino J, Berger ML, Crown W, Goettsch WG, Mullins CD, Willke RJ, Orsini LS. Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials. BMC Med 2021;19:307. [PMID: 34865623 DOI: 10.1186/s12916-021-02176-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Cabrera C, Quélen C, Ouwens M, Hedman K, Rigney U, Quint JK. Evaluating a Cox marginal structural model to assess the comparative effectiveness of inhaled corticosteroids versus no inhaled corticosteroid treatment in chronic obstructive pulmonary disease. Ann Epidemiol 2021:S1047-2797(21)00323-9. [PMID: 34798296 DOI: 10.1016/j.annepidem.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Shin SY, Kim HS. Data Pseudonymization in a Range That Does Not Affect Data Quality: Correlation with the Degree of Participation of Clinicians. J Korean Med Sci 2021;36:e299. [PMID: 34783216 DOI: 10.3346/jkms.2021.36.e299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Patorno E, Schneeweiss S, George MG, Tong X, Franklin JM, Pawar A, Mogun H, Moura LMVR, Schwamm LH. Linking the Paul Coverdell National Acute Stroke Program to commercial claims to establish a framework for real-world longitudinal stroke research. Stroke Vasc Neurol 2021:svn-2021-001134. [PMID: 34750282 DOI: 10.1136/svn-2021-001134] [Reference Citation Analysis]
52 Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol 2021;21:241. [PMID: 34742250 DOI: 10.1186/s12874-021-01440-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
53 McNair D, Lumpkin M, Kern S, Hartman D. Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World. Clin Pharmacol Ther 2022;111:44-51. [PMID: 34655224 DOI: 10.1002/cpt.2449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
54 Wang F, Yang S, Palmer N, Fox K, Kohane IS, Liao KP, Yu KH, Kou SC. Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types. NPJ Precis Oncol 2021;5:82. [PMID: 34508179 DOI: 10.1038/s41698-021-00223-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
55 Gilyarevsky SR. Approaches to Assessing the Quality of Observational Studies of Clinical Practice Based on the Big Data Analysis. Racionalʹnaâ farmakoterapiâ v kardiologii 2021;17:584-93. [DOI: 10.20996/1819-6446-2021-08-01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Alobaida M, Alrumayh A, Oguntade AS, Al-Amodi F, Bwalya M. Cardiovascular Safety and Superiority of Anti-Obesity Medications. Diabetes Metab Syndr Obes 2021;14:3199-208. [PMID: 34285527 DOI: 10.2147/DMSO.S311359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 He W, Fang Y, Wang H, Chan I. Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management. Statistics in Biopharmaceutical Research. [DOI: 10.1080/19466315.2021.1927827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Young J, Wong S, Janjua NZ, Klein MB. Comparing direct acting antivirals for hepatitis C using observational data - Why and how? Pharmacol Res Perspect 2020;8:e00650. [PMID: 32894643 DOI: 10.1002/prp2.650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Zhang Y, Lin LA, Starkopf L, Chen J, Wang WWB. Estimation of causal effect in integrating randomized clinical trial and observational data - An example application to cardiovascular outcome trial. Contemp Clin Trials 2021;107:106492. [PMID: 34175491 DOI: 10.1016/j.cct.2021.106492] [Reference Citation Analysis]
60 Zaccardi F, Davies MJ, Khunti K. The present and future scope of real-world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future? Diabetes Obes Metab 2020;22 Suppl 3:21-34. [PMID: 32250528 DOI: 10.1111/dom.13929] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
61 Patorno E, Schneeweiss S, Wang SV. Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes. Diabetes Obes Metab 2020;22 Suppl 3:45-59. [PMID: 32250527 DOI: 10.1111/dom.13918] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
62 Rahmatian D, Tadrous M. Old dog with new tricks: An introduction to real-world evidence for pharmacists. Am J Health Syst Pharm 2021:zxab261. [PMID: 34153111 DOI: 10.1093/ajhp/zxab261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Romero I, López-Guerrero JA, Pignata S. Real-world experience with trabectedin for the treatment of recurrent ovarian cancer. Expert Rev Anticancer Ther 2021;:1-7. [PMID: 34128757 DOI: 10.1080/14737140.2021.1941890] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Huang Y, Yuan W, Kohane IS, Beaulieu-Jones BK. Illustrating potential effects of alternate control populations on real-world evidence-based statistical analyses. JAMIA Open 2021;4:ooab045. [PMID: 34142018 DOI: 10.1093/jamiaopen/ooab045] [Reference Citation Analysis]
65 Borte M, Anderson-smits C, Hermann C. Update on real-world use of facilitated subcutaneous immunoglobulin and immune globulin subcutaneous (human) 20% solution in patients with immunodeficiencies: poster extracts from the 19th Biennial Meeting of the European Society for Immunodeficiencies. Expert Review of Clinical Immunology 2021;17:7-8. [DOI: 10.1080/1744666x.2021.1913122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Takashima K, Morrison M, Minari J. Reflection on the enactment and impact of safety laws for regenerative medicine in Japan. Stem Cell Reports 2021;16:1425-34. [PMID: 34019814 DOI: 10.1016/j.stemcr.2021.04.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
67 Sun JW, Bourgeois FT, Haneuse S, Hernández-Díaz S, Landon JE, Bateman BT, Huybrechts KF. Development and Validation of a Pediatric Comorbidity Index. Am J Epidemiol 2021;190:918-27. [PMID: 33124649 DOI: 10.1093/aje/kwaa244] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
68 Johansson FD, Collins JE, Yau V, Guan H, Kim SC, Losina E, Sontag D, Stratton J, Trinh H, Greenberg J, Solomon DH. Predicting Response to Tocilizumab Monotherapy in Rheumatoid Arthritis: A Real-world Data Analysis Using Machine Learning. J Rheumatol 2021;48:1364-70. [PMID: 33934070 DOI: 10.3899/jrheum.201626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
69 Simon GE, Platt R, Watanabe JH, Bindman AB, John London A, Horberg M, Hernandez A, Califf RM. When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments? Clin Pharmacol Ther 2021. [PMID: 33895994 DOI: 10.1002/cpt.2253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Franklin JM, Platt R, Dreyer NA, London AJ, Simon GE, Watanabe JH, Horberg M, Hernandez A, Califf RM. When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments? Clin Pharmacol Ther 2021. [PMID: 33826756 DOI: 10.1002/cpt.2255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
71 Müller-Wirtz LM, Volk T. Big Data in Studying Acute Pain and Regional Anesthesia. J Clin Med 2021;10:1425. [PMID: 33916000 DOI: 10.3390/jcm10071425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatol 2021;157:66-73. [PMID: 33263718 DOI: 10.1001/jamadermatol.2020.4202] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
73 Franklin JM, Liaw KL, Iyasu S, Critchlow CW, Dreyer NA. Real-world evidence to support regulatory decision making: New or expanded medical product indications. Pharmacoepidemiol Drug Saf 2021;30:685-93. [PMID: 33675248 DOI: 10.1002/pds.5222] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
74 Liao L, Fang R, Fang F, Zhu XH. Clinical observations of acute onset of myopic optic neuropathy in a real-world setting. Int J Ophthalmol 2021;14:461-7. [PMID: 33747826 DOI: 10.18240/ijo.2021.03.21] [Reference Citation Analysis]
75 Chen J, Ho M, Lee K, Song Y, Fang Y, Goldstein BA, He W, Irony T, Jiang Q, van der Laan M, Lee H, Lin X, Meng Z, Mishra-kalyani P, Rockhold F, Wang H, White R. The Current Landscape in Biostatistics of Real-World Data and Evidence: Clinical Study Design and Analysis. Statistics in Biopharmaceutical Research. [DOI: 10.1080/19466315.2021.1883474] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
76 Levenson M, He W, Chen J, Fang Y, Faries D, Goldstein BA, Ho M, Lee K, Mishra-kalyani P, Rockhold F, Wang H, Zink RC. Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment. Statistics in Biopharmaceutical Research. [DOI: 10.1080/19466315.2021.1883473] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
77 Vanner EA, Sun CQ, McSoley MJ, Persad PJ, Feuer WJ, Lum F, Kelly S, Parrish RK, Chang TC, Gedde SJ. Reply to Comment on: The Tube Versus Trabeculectomy IRIS Registry Study: Cohort Selection and Follow-up and Comparisons to the Randomized Controlled Trial. Am J Ophthalmol 2021:S0002-9394(21)00094-5. [PMID: 33676946 DOI: 10.1016/j.ajo.2021.02.029] [Reference Citation Analysis]
78 Huang Y, Yuan W, Kohane IS, Beaulieu-jones BK. Illustrating Potential Effects of Alternate Control Populations on Real-World Evidence-based Statistical Analyses.. [DOI: 10.1101/2021.02.21.432172] [Reference Citation Analysis]
79 Franklin JM, Lin KJ, Gatto NM, Rassen JA, Glynn RJ, Schneeweiss S. Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. Clin Pharmacol Ther 2021;109:816-28. [PMID: 33529354 DOI: 10.1002/cpt.2185] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
80 Dworkin RH, Kerns RD, McDermott MP, Turk DC, Veasley C. The ACTTION Guide to Clinical Trials of Pain Treatments, part II: mitigating bias, maximizing value. Pain Rep 2021;6:e886. [PMID: 33521484 DOI: 10.1097/PR9.0000000000000886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
81 Fanaroff AC, Califf RM, Harrington RA, Granger CB, McMurray JJV, Patel MR, Bhatt DL, Windecker S, Hernandez AF, Gibson CM, Alexander JH, Lopes RD. Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week. J Am Coll Cardiol 2020;76:580-9. [PMID: 32731936 DOI: 10.1016/j.jacc.2020.05.069] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 18.5] [Reference Citation Analysis]
82 Crown WH, Bierer BE. Real-World Evidence: Understanding Sources of Variability Through Empirical Analysis. Value Health 2021;24:116-7. [PMID: 33431144 DOI: 10.1016/j.jval.2020.11.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
83 Wang SV, Pinheiro S, Hua W, Arlett P, Uyama Y, Berlin JA, Bartels DB, Kahler KH, Bessette LG, Schneeweiss S. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ 2021;372:m4856. [PMID: 33436424 DOI: 10.1136/bmj.m4856] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
84 Bykov K, Li H, Kim S, Vine SM, Lo Re V 3rd, Gagne JJ. Drug-Drug Interaction Surveillance Study: Comparing Self-Controlled Designs in Five Empirical Examples in Real-World Data. Clin Pharmacol Ther 2021;109:1353-60. [PMID: 33245789 DOI: 10.1002/cpt.2119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, Pawar A, Bessette LG, Lee H, Garry EM, Gautam N, Schneeweiss S. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation 2021;143:1002-13. [PMID: 33327727 DOI: 10.1161/CIRCULATIONAHA.120.051718] [Cited by in Crossref: 81] [Cited by in F6Publishing: 89] [Article Influence: 27.0] [Reference Citation Analysis]
86 Fang Y. Two basic statistical strategies of conducting causal inference in real-world studies. Contemp Clin Trials 2020;99:106193. [PMID: 33153972 DOI: 10.1016/j.cct.2020.106193] [Reference Citation Analysis]
87 Radawski CA, Hammad TA, Colilla S, Coplan P, Hornbuckle K, Freeman E, Smith MY, Sobel RE, Bahri P, Arias AE, Bennett D. The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies. Pharmacoepidemiol Drug Saf 2020;29:1532-9. [PMID: 33146901 DOI: 10.1002/pds.5167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
88 Mina A. Big data e inteligencia artificial en el futuro manejo de pacientes. ¿Por dónde empezar? ¿En qué punto nos encontramos? ¿Quo tendimus? Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2020;1. [DOI: 10.1515/almed-2020-0052] [Reference Citation Analysis]
89 Mina A. Big data and artificial intelligence in future patient management. How is it all started? Where are we at now? Quo tendimus? Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2020;1. [DOI: 10.1515/almed-2020-0014] [Reference Citation Analysis]
90 Gerhard T, Stroup TS, Correll CU, Setoguchi S, Strom BL, Huang C, Tan Z, Crystal S, Olfson M. Mortality risk of antipsychotic augmentation for adult depression. PLoS One 2020;15:e0239206. [PMID: 32997687 DOI: 10.1371/journal.pone.0239206] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
91 Tazare J, Smeeth L, Evans SJW, Williamson E, Douglas IJ. Implementing high-dimensional propensity score principles to improve confounder adjustment in UK electronic health records. Pharmacoepidemiol Drug Saf 2020;29:1373-81. [PMID: 32926504 DOI: 10.1002/pds.5121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Sheffield KM, Dreyer NA, Murray JF, Faries DE, Klopchin MN. Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions. J Comp Eff Res 2020;9:1043-50. [PMID: 32914653 DOI: 10.2217/cer-2020-0161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
93 Fang Y, He W, Hu X, Wang H. A method for sample size calculation via E-value in the planning of observational studies. Pharm Stat 2021;20:163-74. [PMID: 32816399 DOI: 10.1002/pst.2064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
94 Fralick M, Bartsch E, Darrow JJ, Kesselheim AS. Understanding when real world data can be used to replicate a clinical trial: A cross-sectional study of medications approved in 2011. Pharmacoepidemiol Drug Saf 2020;29:1273-8. [PMID: 32798299 DOI: 10.1002/pds.5086] [Reference Citation Analysis]
95 Song TJ, Kim J. Effect of Statins on the Risk of Poststroke Pneumonia: National Population-Based Cohort Study. Infect Drug Resist 2020;13:2689-98. [PMID: 32982323 DOI: 10.2147/IDR.S258420] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
96 Fang Y, He W, Wang H, Wu M. Key considerations in the design of real-world studies. Contemp Clin Trials 2020;96:106091. [PMID: 32717351 DOI: 10.1016/j.cct.2020.106091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
97 van Laar SA, Gombert-Handoko KB, Guchelaar HJ, Zwaveling J. An Electronic Health Record Text Mining Tool to Collect Real-World Drug Treatment Outcomes: A Validation Study in Patients With Metastatic Renal Cell Carcinoma. Clin Pharmacol Ther 2020;108:644-52. [PMID: 32575147 DOI: 10.1002/cpt.1966] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
98 Higgins D, Madai VI. From Bit to Bedside: A Practical Framework for Artificial Intelligence Product Development in Healthcare. Advanced Intelligent Systems 2020;2:2000052. [DOI: 10.1002/aisy.202000052] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
99 Magrey MN, Singh DK. Drs. Singh and Magrey reply. J Rheumatol 2020;47:1150.2-1150. [DOI: 10.3899/jrheum.200048] [Reference Citation Analysis]
100 Stewart M, Norden AD, Dreyer N, Henk HJ, Abernethy AP, Chrischilles E, Kushi L, Mansfield AS, Khozin S, Sharon E, Arunajadai S, Carnahan R, Christian JB, Miksad RA, Sakoda LC, Torres AZ, Valice E, Allen J. An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. JCO Clin Cancer Inform 2019;3:1-15. [PMID: 31335166 DOI: 10.1200/CCI.18.00155] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 16.7] [Reference Citation Analysis]
101 Hodgkinson VL, Oskoui M, Lounsberry J, M'Dahoma S, Butler E, Campbell C, MacKenzie A, McMillan HJ, Simard L, Vajsar J, Brais B, Chapman KM, Chrestian N, Crone M, Dobrowolski P, Dojeiji S, Dowling JJ, Dupré N, Genge A, Gonorazky H, Hasal S, Izenberg A, Johnston W, Leung E, Lochmüller H, Mah JK, Marerro A, Massie R, McAdam L, McCormick A, Melanson M, Mezei MM, Nguyen CE, O'Connell C, O'Ferrall EK, Pfeffer G, Phan C, Plamondon S, Poulin C, Rodrigue X, Schellenberg KL, Selby K, Sheriko J, Shoesmith C, Smith G, Taillon M, Taylor S, Warman Chardon J, Worley S, Korngut L. A National Spinal Muscular Atrophy Registry for Real-World Evidence. Can J Neurol Sci 2020;47:810-5. [PMID: 32493524 DOI: 10.1017/cjn.2020.111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
102 Ye Y, Manne S, Bennett D. Identifying Patients With Inflammatory Bowel Diseases in an Administrative Health Claims Database: Do Algorithms Generate Similar Findings? Inquiry 2019;56:46958019887816. [PMID: 31744340 DOI: 10.1177/0046958019887816] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
103 Gatti M, Bianchin M, Raschi E, De Ponti F. Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review. European Journal of Internal Medicine 2020;75:60-70. [DOI: 10.1016/j.ejim.2020.01.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
104 Castaldelli-maia JM, Riba MB, Lecic-tosevski D, Chandra PS, Cia A, Tyrer PJ, Heun R, Szabo CP. The Main Gaps for Randomized-controlled Trials in Psychiatry: A Bibliometric Study. Global Psychiatry 2020;3:51-63. [DOI: 10.2478/gp-2020-0008] [Reference Citation Analysis]
105 Cahn A, Raz I, Bonaca M, Mosenzon O, Murphy SA, Yanuv I, Rozenberg A, Wilding JPH, Bhatt DL, McGuire DK, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Jermendy G, Hadjadj S, Langkilde AM, Sabatine MS, Wiviott SD, Leiter LA. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. Diabetes Obes Metab 2020;22:1357-68. [PMID: 32239659 DOI: 10.1111/dom.14041] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
106 Spoendlin J, Desai RJ, Franklin JM, Glynn RJ, Payne E, Schneeweiss S. Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. Clin Pharmacol Ther 2020;108:874-84. [PMID: 32320482 DOI: 10.1002/cpt.1861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
107 Magaret A, Warden M, Simon N, Heltshe S, Mayer-Hamblett N. Real-world evidence in cystic fibrosis modulator development: Establishing a path forward. J Cyst Fibros 2020;19:e11-2. [PMID: 32291159 DOI: 10.1016/j.jcf.2020.03.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
108 Ollivier M, Jacquet C, Pailhe R, Cognault J, Cavaignac E, Seil R. Higher re-rupture rate in quadriceps tendon ACL reconstruction surgeries performed in Denmark: let’s return to the mean. Knee Surg Sports Traumatol Arthrosc 2020;28:3655-6. [DOI: 10.1007/s00167-020-05961-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
109 Forbes SP, Dahabreh IJ. Benchmarking Observational Analyses Against Randomized Trials: a Review of Studies Assessing Propensity Score Methods. J Gen Intern Med 2020;35:1396-404. [PMID: 32193818 DOI: 10.1007/s11606-020-05713-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
110 Lasky T, Carleton B, Horton DB, Kelly LE, Bennett D, Czaja AS, Gifkins D, Osokogu OU, McMahon AW. Real-World Evidence to Assess Medication Safety or Effectiveness in Children: Systematic Review. Drugs Real World Outcomes 2020;7:97-107. [PMID: 32112359 DOI: 10.1007/s40801-020-00182-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
111 Meregaglia M, Ciani O, Banks H, Salcher-Konrad M, Carney C, Jayawardana S, Williamson P, Fattore G. A scoping review of core outcome sets and their 'mapping' onto real-world data using prostate cancer as a case study. BMC Med Res Methodol 2020;20:41. [PMID: 32103725 DOI: 10.1186/s12874-020-00928-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
112 Zhang P, Chiang C, Quinney S, Donneyong M, Lu B, Huang LF, Cheng F. The Concurrent Initiation of Medications Is Associated with Discontinuation of Buprenorphine Treatment for Opioid Use Disorder.. [DOI: 10.1101/2020.01.15.20017715] [Reference Citation Analysis]
113 Fralick M, Chen SK, Patorno E, Kim SC. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Ann Intern Med 2020;172:186-94. [PMID: 31931526 DOI: 10.7326/M19-2610] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
114 van Trijffel E, A B Oostendorp R, Elvers JWH. Routinely collected data as real-world evidence for physiotherapy practice. Physiother Theory Pract 2019;35:805-9. [PMID: 31218943 DOI: 10.1080/09593985.2019.1615678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
115 Fang Y, Wang H, He W. A Statistical Roadmap for Journey from Real-World Data to Real-World Evidence. Ther Innov Regul Sci 2020;54:749-57. [DOI: 10.1007/s43441-019-00008-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
116 Patorno E, Najafzadeh M, Pawar A, Franklin JM, Déruaz-Luyet A, Brodovicz KG, Santiago Ortiz AJ, Bessette LG, Kulldorff M, Schneeweiss S. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care. Endocrinol Diabetes Metab 2020;3:e00103. [PMID: 31922030 DOI: 10.1002/edm2.103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
117 Kent DM, Paulus JK, van Klaveren D, D'Agostino R, Goodman S, Hayward R, Ioannidis JPA, Patrick-Lake B, Morton S, Pencina M, Raman G, Ross JS, Selker HP, Varadhan R, Vickers A, Wong JB, Steyerberg EW. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. Ann Intern Med 2020;172:35-45. [PMID: 31711134 DOI: 10.7326/M18-3667] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 23.5] [Reference Citation Analysis]
118 Kent DM, van Klaveren D, Paulus JK, D'Agostino R, Goodman S, Hayward R, Ioannidis JPA, Patrick-Lake B, Morton S, Pencina M, Raman G, Ross JS, Selker HP, Varadhan R, Vickers A, Wong JB, Steyerberg EW. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration. Ann Intern Med 2020;172:W1-W25. [PMID: 31711094 DOI: 10.7326/M18-3668] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 11.5] [Reference Citation Analysis]
119 Bate A, Trifirò G, Avillach P, Evans SJ. Data Mining and Other Informatics Approaches to Pharmacoepidemiology. Pharmacoepidemiology 2019. [DOI: 10.1002/9781119413431.ch27] [Reference Citation Analysis]
120 Harris RA, Kranzler HR, Chang KM, Doubeni CA, Gross R. Long-term use of hydrocodone vs. oxycodone in primary care. Drug Alcohol Depend 2019;205:107524. [PMID: 31707268 DOI: 10.1016/j.drugalcdep.2019.06.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
121 Batra A, Cheung WY. Role of real-world evidence in informing cancer care: lessons from colorectal cancer. Curr Oncol. 2019;26:S53-S56. [PMID: 31819710 DOI: 10.3747/co.26.5625] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
122 Franklin JM, Pawar A, Martin D, Glynn RJ, Levenson M, Temple R, Schneeweiss S. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. Clin Pharmacol Ther 2020;107:817-26. [PMID: 31541454 DOI: 10.1002/cpt.1633] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 10.5] [Reference Citation Analysis]
123 Eichler HG, Koenig F, Arlett P, Enzmann H, Humphreys A, Pétavy F, Schwarzer-Daum B, Sepodes B, Vamvakas S, Rasi G. Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation. Clin Pharmacol Ther 2020;107:773-9. [PMID: 31574163 DOI: 10.1002/cpt.1638] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 9.5] [Reference Citation Analysis]
124 Schneeweiss S, Glynn RJ. Real-World Data Analytics Fit for Regulatory Decision-Making. Am J Law Med 2018;44:197-217. [PMID: 30106649 DOI: 10.1177/0098858818789429] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
125 Sheu J, Tsai M, Erickson SR, Wu C. Association between Anticholinergic Medication Use and Risk of Dementia among Patients with Parkinson's Disease. Pharmacotherapy 2019;39:798-808. [DOI: 10.1002/phar.2305] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
126 Breckenridge AM, Breckenridge RA, Peck CC. Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation. Br J Clin Pharmacol 2019;85:1874-7. [PMID: 31290181 DOI: 10.1111/bcp.14026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
127 Crown WH. Real-World Evidence, Causal Inference, and Machine Learning. Value Health 2019;22:587-92. [PMID: 31104739 DOI: 10.1016/j.jval.2019.03.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
128 Novack GD. Real world evidence for pharmaceuticals. The Ocular Surface 2019;17:584-8. [DOI: 10.1016/j.jtos.2019.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
129 Zauderer MG, Grigorenko A, May P, Kastango N, Wagner I, Caroline A, Kris MG. Creating a Synthetic Clinical Trial: Comparative Effectiveness Analyses Using an Electronic Medical Record. JCO Clin Cancer Inform 2019;3:1-10. [PMID: 31225984 DOI: 10.1200/CCI.19.00037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
130 Daniel G. Building Trust in RWE Will Support Clearer Regulatory Uses. Ther Innov Regul Sci 2019;53:417-9. [PMID: 31213090 DOI: 10.1177/2168479019859948] [Reference Citation Analysis]
131 Bykov K, He M, Franklin JM, Garry EM, Seeger JD, Patorno E. Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data. Diabetes Obes Metab 2019;21:2029-38. [PMID: 31062453 DOI: 10.1111/dom.13766] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
132 O'Donnell PH, Reynolds KS. Breaking Down Barriers to Effective Patient Care. Clin Pharmacol Ther 2018;103:360-4. [PMID: 29417567 DOI: 10.1002/cpt.1026] [Reference Citation Analysis]
133 Schneeweiss S. Real‐World Evidence of Treatment Effects: The Useful and the Misleading. Clin Pharmacol Ther 2019;106:43-4. [DOI: 10.1002/cpt.1405] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
134 Lasky T. Ascertaining vaccine exposure at the brand level using real-world data. Pharmacoepidemiol Drug Saf 2019;28:763-5. [PMID: 30916840 DOI: 10.1002/pds.4776] [Reference Citation Analysis]
135 Fralick M, Kesselheim AS, Avorn J, Schneeweiss S. Use of Health Care Databases to Support Supplemental Indications of Approved Medications. JAMA Intern Med. 2018;178:55-63. [PMID: 29159410 DOI: 10.1001/jamainternmed.2017.3919] [Cited by in Crossref: 72] [Cited by in F6Publishing: 79] [Article Influence: 18.0] [Reference Citation Analysis]
136 Franklin JM, Glynn RJ, Martin D, Schneeweiss S. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. Clin Pharmacol Ther 2019;105:867-77. [PMID: 30636285 DOI: 10.1002/cpt.1351] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 20.5] [Reference Citation Analysis]
137 Gerstein HC, Mcmurray J, Holman RR. Real-world studies no substitute for RCTs in establishing efficacy. The Lancet 2019;393:210-1. [DOI: 10.1016/s0140-6736(18)32840-x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 16.3] [Reference Citation Analysis]
138 Colin L, Smith B. Statistical Considerations in Proof-of-Concept Studies. Statistical Methods in Biomarker and Early Clinical Development 2019. [DOI: 10.1007/978-3-030-31503-0_11] [Reference Citation Analysis]
139 Rassen JA, Bartels DB, Schneeweiss S, Patrick AR, Murk W. Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. Clin Epidemiol 2019;11:1-15. [PMID: 30588119 DOI: 10.2147/CLEP.S181242] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 9.0] [Reference Citation Analysis]
140 Stapff MP. Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes. World J Diabetes 2018; 9(12): 252-257 [PMID: 30588287 DOI: 10.4239/wjd.v9.i12.252] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
141 Kent DM, Steyerberg E, van Klaveren D. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. BMJ 2018;363:k4245. [PMID: 30530757 DOI: 10.1136/bmj.k4245] [Cited by in Crossref: 148] [Cited by in F6Publishing: 155] [Article Influence: 29.6] [Reference Citation Analysis]
142 Huybrechts KF, Gopalakrishnan C, Franklin JM, Zint K, Franca LR, Bartels DB, Landon J, Schneeweiss S. Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records. Clin Pharmacol Ther 2019;105:979-93. [PMID: 30341980 DOI: 10.1002/cpt.1256] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
143 Santucci C, Franchi M, Staszewsky L, La Vecchia C, Latini R, Merlino L, Corrao G, Bosetti C. Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study. Diabetes Res Clin Pract 2018;146:172-9. [PMID: 30332619 DOI: 10.1016/j.diabres.2018.10.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
144 Dumontier C, Kim D. Continuing the Effort to Predict Risk of Future Unplanned Healthcare Use in Older Adults. J Am Geriatr Soc 2018;66:2032-2034. [DOI: 10.1111/jgs.15514] [Reference Citation Analysis]
145 Serrano P, Hartmann M, Schmitt E, Franco P, Amexis G, Gross J, Mayer-Nicolai C. Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. Clin Pharmacol Ther 2019;105:582-97. [PMID: 29923615 DOI: 10.1002/cpt.1123] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
146 Weberpals J, Jansen L, Silversmit G, Verbeeck J, van der Geest L, Vissers PA, Zadnik V, Brenner H. Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients. Clin Epidemiol 2018;10:1109-25. [PMID: 30214315 DOI: 10.2147/CLEP.S160973] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
147 Raschi E, Poluzzi E, Fadini GP, Marchesini G, De Ponti F. Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? Diabetes Obes Metab 2018;20:2711-23. [PMID: 30003655 DOI: 10.1111/dom.13468] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
148 Adimadhyam S, Lee TA, Calip GS, Smith Marsh DE, Layden BT, Schumock GT. Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study. Diabetes Obes Metab 2018;20:2792-9. [DOI: 10.1111/dom.13459] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
149 Schneeweiss S. Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects. Clin Epidemiol 2018;10:771-88. [PMID: 30013400 DOI: 10.2147/CLEP.S166545] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
150 Yuan H, Ali MS, Brouwer ES, Girman CJ, Guo JJ, Lund JL, Patorno E, Slaughter JL, Wen X, Bennett D; ISPE Comparative Effectiveness Research Special Interest Group. Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG). Clin Pharmacol Ther 2018;104:239-41. [PMID: 29733448 DOI: 10.1002/cpt.1086] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
151 Nischal KK. Practice patterns in pediatric cataract management: Time for real world data. Indian J Ophthalmol 2017;65:779-81. [PMID: 28905817 DOI: 10.4103/ijo.IJO_816_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
152 Smith B, Sander O. Innovation in the Design of Clinical Trials: Necessary for Innovation in Medicine. Clin Pharmacol Ther 2017;102:880-2. [PMID: 29119553 DOI: 10.1002/cpt.868] [Reference Citation Analysis]